Search results for "ANEM"

showing 10 items of 405 documents

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical-pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found i…

AdultMaleCancer Researchmedicine.medical_specialtyLymphomaAnemiamedicine.medical_treatmentSplenectomysplenic marginal zone lymphomaGastroenterologyBone marrow biopsyIntrasinusoidalInternal medicinemedicineHumansLymphocytesLeukocytosisSplenic marginal zone lymphomaSurvival rateAgedAged 80 and overLeukopeniabusiness.industrySplenic Neoplasmssplenic marginal zone lymphoma; PrognosisSplenic lymphoma with villous lymphocytesMiddle AgedPrognosismedicine.diseaseSplenic NeoplasmSurgerySurvival Ratemedicine.anatomical_structureOncologySplenectomySplenic lymphoma with villous lymphocyteLymphocyteFemaleBone marrowmedicine.symptombusinessHumanCancer
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor …

1999

The first-line treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS syndrome) induces a response and survival rate of approximately 85%, even if a considerable number of patients relapse; nevertheless, a number of these patients are resistant to conventional management. Immunoablation followed by stem cell transplantation has been shown to be capable of inducing remissions in a large spectrum of experimental autoimmune disorders. We report here the case of a 20-year-old male patient with the TTP-HUS syndrome who was resistant to conventional treatment and was transplanted with autologous immunoselected CD34+ PBPC after conditioning with cyclosphosphamide, anti…

AdultMaleHemolytic anemiaLymphocyteThrombotic thrombocytopenic purpuraAntigens CD34Transplantation AutologousPrednisonehemic and lymphatic diseasesHumansMedicineProgenitor cellSurvival rateTransplantationPurpura Thrombotic Thrombocytopenicbusiness.industryHematopoietic Stem Cell TransplantationHematologyHematopoietic Stem Cellsmedicine.diseaseTransplantationmedicine.anatomical_structureHemolytic-Uremic SyndromeImmunologyStem cellbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spec…

2005

Summary High oxidative stress status (OSS) is known to be one of the most important factors determining cell injury and consequent organ damage in thalassaemic patients with secondary iron overload. Using an innovative hydroxylamine ‘radical probe’ capable of efficiently trapping majority of oxygen-radicals including superoxide we measured, by electron paramagnetic resonance (EPR) spectroscopy, OSS in peripheral blood of 38 thalassaemic patients compared with sex-/age-matched healthy controls. Thalassaemic patients showed sixfold higher EPR values of OSS than controls. Significantly higher EPR values of OSS were observed in those with a severe phenotype (thalassaemia major, transfusion-depe…

AdultMaleHemolytic anemiamedicine.medical_specialtyIron Overloadmedicine.disease_causelaw.inventionchemistry.chemical_compoundHydroxylaminelawInternal medicineOXIDATIVE STRESS STATUSmedicineHumansB-THALASSAEMIC PATIENTSElectron paramagnetic resonanceChelating AgentsAnalysis of VarianceHematologySuperoxidebeta-ThalassemiaElectron Spin Resonance SpectroscopyHYDROXYLAMINEHematologyCHELATING THERAPYmedicine.diseaseOxidative StressELECTRON PARAMAGNETIC RESONANCEEndocrinologyHemoglobinopathychemistryCase-Control StudiesImmunologyFemaleDeferiproneOxidative stressBritish Journal of Haematology
researchProduct

Serum and fecal pancreatic enzymes in beta-thalassemia major

1997

This study, using indirect tests, demonstrated that exocrine pancreatic function is impaired in a proportion of patients with beta-thalassemia major (TM), though this impairment is generally mild or moderate.Impaired structure and function of the exocrine pancreas has been reported in patients with Beta-thalassemia major.In this study we measured fecal fats and serum and fecal pancreatic enzymes in 30 patients (13 M, 17 F) with TM, mean age 22.1 yr (range 14-39) and compared them with those of a matched group of healthy controls. Results were correlated with age, serum ferritin, blood transfusion, and various nutritional parameters. Enzymes assays included: serum pancreatic amylase (PA), li…

AdultMaleHemolytic anemiamedicine.medical_specialtyPancreatic diseaseAdolescentHydrolasesGastroenterologyFatsPathogenesisFecesEndocrinologyInternal medicinemedicineChymotrypsinHumansTrypsinFeceschemistry.chemical_classificationPancreatic Elastasebusiness.industrybeta-ThalassemiaGastroenterologyBeta thalassemiaLipasemedicine.diseaseHemoglobinopathyEnzymeEndocrinologyOncologychemistryAmylasesExocrine Pancreatic InsufficiencyFemalebusinessPancreatic enzymesInternational Journal of Pancreatology
researchProduct

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-fi…

2017

Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leuk…

AdultMaleIneffective erythropoiesismyalgiamedicine.medical_specialtyPediatricsTime FactorsMaximum Tolerated DoseAnemiaActivin Receptors Type IIRecombinant Fusion ProteinsKaplan-Meier EstimateLower riskmedicine.disease_causeRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineGermanyInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAdverse effectAgedProportional Hazards ModelsDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesAnemiaMiddle AgedPrognosismedicine.diseaseSurvival AnalysisActivinsImmunoglobulin Fc FragmentsTreatment OutcomeOncologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemalemedicine.symptombusiness030215 immunologyThe Lancet Oncology
researchProduct

Juvenile Xanthogranuloma and Nevus Anemicus in the Diagnosis of Neurofibromatosis Type 1

2013

Importance The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical criteria. However, they are of limited value before the age of 2 years. Juvenile xanthogranuloma (JXG) and nevus anemicus (NA) are commonly observed in children with NF1 and may be useful diagnostic clues. Objectives To evaluate the frequency of JXG and NA, to describe their clinical features, and to determine their diagnostic value in patients with NF1. Design, Setting, and Participants Retrospective medical record review of outpatients seen between January 1, 2005, and December 31, 2011. University hospital dermatology department affiliated with the French NF1 referral center network. Patients with NF1 diagn…

AdultMalePediatricsmedicine.medical_specialtyNeurofibromatosis 1Skin NeoplasmsAdolescentJuvenile xanthogranulomaChronic myelomonocytic leukemiaDermatologyHospitals UniversityYoung AdultmedicineHumansSex organYoung adultNeurofibromatosisChildNevusNevus anemicusAgedRetrospective Studiesbusiness.industryMedical recordAge FactorsInfant NewbornInfantRetrospective cohort studyMiddle Agedmedicine.diseaseEarly DiagnosisChild PreschoolFemaleFrancebusinessJAMA Dermatology
researchProduct

Metabolic Evaluation of 94 Patients 5 to 16 Years After Ileocecal Pouch (Mainz Pouch 1) Continent Urinary Diversion

2003

PURPOSE In continent urinary diversion metabolic disturbances may be encountered in long-term followup. We evaluated metabolic consequences in patients with a minimum followup of 5 years after Mainz pouch 1 urinary diversion.At our institution continent urinary diversion using the ileocecal segment was performed between 1983 and 1995 in 458 patients. A total of 94 patients with an ileocecal pouch for a minimum of 5 years were reevaluated for metabolic changes. Median followup was 9.0 years. Routine laboratory parameters, blood gas analysis, vitamin B12, vitamin D25, cross-laps, bone specific alkaline phosphatase, osteocalcin and propeptide of type I collagen were obtained. Bone density was …

AdultMalePhosphopeptidesmedicine.medical_specialtyBone diseaseBone densityUrologymedicine.medical_treatmentUrinary systemOsteocalcinOsteoporosisSodium CitratePostoperative ComplicationsCalcitriolBone DensityReference ValuesPotassium CitrateHumansMedicineCitratesMegaloblastic anemiaAgedbusiness.industryUrinary Reservoirs ContinentUrinary diversionMiddle AgedAlkaline Phosphatasemedicine.diseaseSurgeryVitamin B 12FemaleCollagenBlood Gas AnalysisPouchAcidosisEnergy MetabolismbusinessContinent Urinary DiversionProcollagenFollow-Up StudiesJournal of Urology
researchProduct

First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomiz…

2009

Abstract Background Quality of life (QoL) has gained greater importance in the management of metastatic non-small-cell lung cancer due to the palliative nature of treatment. Docetaxel (DCT) and cisplatin (CDDP) doublet has been reported to be associated to a better QoL than the weekly vinorelbine (VNR) and CDDP regimen. Recently a newer more tolerated schedule of the VNR/CDDP regimen has been published and is widely employed in medical practice. The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically. Methods Patients received CDDP 75mg/m 2 plus DCT 75mg/m 2 on day 1 every weeks (arm A) or CDD…

AdultMalePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentDocetaxelNeutropeniaVinblastineVinorelbineClinical ProtocolsQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedChemotherapybusiness.industryAnemiaVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRegimenOncologyDocetaxelDisease ProgressionQuality of LifeFemaleTaxoidsCisplatinbusinessFebrile neutropeniamedicine.drugLung Cancer
researchProduct

Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia

2021

AdultMaleRiskPediatricsmedicine.medical_specialtyIron OverloadAnemiabusiness.industryThalassemiabeta-ThalassemiaAnemiaHematologyKaplan-Meier Estimatemedicine.diseaseYoung AdultTransfusion dependencemedicineRisk of mortalityHumansBlood TransfusionFemaleMortalitybusinessHuman
researchProduct